Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage European companies.

Our current portfolio comprises biotech, medtech and diagnostics companies, all working to develop truly disruptive solutions for high unmet medical needs.

Dezima and Acerta, multi-billion Euro success stories

BioGeneration was co-founder and investor in two of the most successful biotech startups in Europe: Acerta Pharma and Dezima Pharma. Acerta Pharma develops a new drug for the treatment of hematologic malignancies (leukemia) and was sold to AstraZeneca for up to US$ 7 billion. Dezima Pharma is developing a treatment for of a cardiovascular disorder (dyslipidemia) and was sold to Amgen for a deal amount of up to US$ 1.5 billion.

Shaping new life-science ventures

Our varied and complementary experience has been gained from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ImmunoGen

May 14, 2018

AMSTERDAM, NETHERLANDS – May 14, 2018 – Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc. Dr. Lambert joined ImmunoGen Inc. in 1987 and...

Scenic Biotech: one of Nature Biotechnology Academic Spinouts of 2017

Apr 19, 2018

We congratulate Scenic Biotech on being one of Nature Biotechnology Academic Spinouts of 2017. Nature Biotechnology: "... we believe these companies represent some of the best (and most richly financed) science that was commercialized from academia in 2017". Please...

Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases

Mar 13, 2018

Advancing Escalier’s drug candidates through human proof-of-concept studies NIJMEGEN, The Netherlands and ENCINITAS, California, – Escalier Biosciences BV, a privately held biopharmaceutical company, today announced the closing of a $19 million Series B financing. The...

BGV co-leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme

Dec 12, 2017

Lead drug icosabutate, in-licensed from Pronova BioPharma AS Phase IIb-ready at the end of 2018 Investment syndicate led by Forbion and BGV, and includes Novo Seeds and New Science Ventures Naarden, The Netherlands, 12 December 2017 – BGV, an early stage European...

News overview

Next events

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Event overview

Latest investments

Portfolio